[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: Three Major Advances in Multiple Sclerosis I am Dr. Andrew Wilner, reporting from the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. I am here today with Dr. Fred Lublin, Saunders Family Professor of Neurology at the Icahn School of Medicine of Mount Sinai in New York City and Director of the Corrine Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, New York. I am also here with Dr. Robert Fox, Associate Professor at the Cleveland Clinic Lerner College of Medicine and Staff Neurologist at the Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, Ohio. Welcome, gentlemen. What presentations at this year's ECTRIMS meeting did you find most interesting? Fred D. Lublin, MD: Walking over here, Bob and I were talking about the 2 themes that impressed us the most: progressive disease and the role of relapses. Robert J. Fox, MD: There is an increasing focus on this unmet need. We approve therapies for MS, and they are all in the relapsing stage focus. We really don't have options for progressive MS. A lot of studies have looked at how to evaluate progressive MS and what biomarkers to use. Some potential therapies are still in trials and we are waiting for them to come out. Radiologically Isolated Syndrome of MS Dr. Fox: One area of progressive MS that we learned about was the radiologically isolated syndrome.[1,2] These are patients who have an MRI of the brain done for other reasons, and they have lesions that look for all the world like MS, but they don't have symptoms of MS, and so we call that an "isolated syndrome of the MRI" or "radiologically isolated syndrome." We have known for quite a while that some of those patients go on to develop relapsing-remitting MS, and for the first time we heard about a small proportion of patients who go on to develop primary progressive MS. It is not a large proportion, but there are indeed some patients who have inflammation without any symptoms for years -- some up to 15 years -- and then they develop primary progressive MS. It really drives home that this disease probably starts long before patients first develop symptoms. Dr. Lublin: One thing that came up from that study is the fact that patients with progressive MS can have a lot of disease in the brain. Topic Alert Drug & Reference Information Ophthalmologic Manifestations of Multiple Sclerosis Magnetic Resonance Imaging in Acute Stroke Optic Neuritis Imaging The Role of Relapses Dr. Lublin: The other theme that came up was that earlier studies suggested that the relapses didn't matter once the patient hit a progressive phase, that it was the progression that was driving the disability. In progressive disease it is the slow progression that drives most of the disability, but it turns out that you can't ignore the relapses. There was a study from the Mayo Clinic[3] in which they interrogated their extensive database and looked at individuals with primary progressive MS and secondary progressive MS who had relapses during the course of their progression. The only difference between them was that the patient with primary progressive MS, who then has a relapse, then has progressive relapsing MS. In both cases the relapses matter. Patients did worse if they were having relapses in addition to progressive disease, and this highlights an inflammatory component to relapsing MS. The presenters raised the possibility that this could have therapeutic implications for an area of MS where we really don't have very good therapies. The other issue that came up was the role of relapses and how we can modify them. In all of our relapsing clinical trials, the agents that have succeeded reduced the number of relapses, but how about the severity of relapses? Dr. Fox: A study that you were involved in, Fred, looked at the severity of relapses in patients in the phase 3 clinical trials for teriflunomide and natalizumab,[4,5] and in those 2 trials the severity of the relapses was less and the patients seemed to recover better when they were on active treatment than when they were on placebo. So we are now moving beyond just counting the number of relapses to also looking at the amount of injury that is incurred through the relapse. It is encouraging that our therapies not only reduce the numbers but also make patients better at the end and make the relapses less severe. Environmental Triggers Dr. Lublin: With respect to the role of environmental agents in MS, there was a discussion of how the incidence of MS has increased and the gender frequency has changed, so MS is becoming more frequent in women than in men. Because this has occurred relatively recently in time, it suggests that it can't be a genetic feature but rather an environmental feature. Dr. Fox: Vitamin D appears to have an impact on disease.[6] Even in patients who are on therapy, low vitamin D is associated with a worse disease course and provides some ideas of things that we might be able to combine with our standard therapy, such as vitamin D supplementation. We also saw that not only does smoking predispose to getting MS, which we have known for a bit of time, but also it predisposes to MS being worse once it develops. It teaches us an important lesson that we should remember to encourage patients to stop smoking, and for those who are still smoking, that should be part of our care of their MS.[7] Dr. Wilner: I would like to thank both of you for your comments and insights. This is Dr. Andrew Wilner, reporting from the ECTRIMS meeting in Copenhagen, Denmark. Post Comment Private Reply Ignore Thread
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||